Literature DB >> 17140827

Unilateral lens extraction for high anisometropic myopia in children and adolescents.

Asim Ali1, Eric Packwood, Gregg Lueder, Lawrence Tychsen.   

Abstract

INTRODUCTION: A subpopulation of children with anisometropic myopia, amblyopia, and neurobehavioral disorders is noncompliant with spectacle wear and ill-suited to correction using contact lenses. We report the results of refractive surgery in a series of these children treated using lensectomy alone (clear lens extraction) or lensectomy with simultaneous implantation of an intraocular lens (refractive lens exchange).
METHODS: Clinical course and outcome data were collated retrospectively in a group of 7 children and adolescents (mean age, 9.1 years; range, 4-20 years) with neurobehavioral disorders and noncompliance with spectacle wear for anisometropic myopia. Myopia in the 7 eyes ranged -11.9 to -24.5 D (mean, -16.7 D). Goal refraction was 0 to + 4 D. Correction was achieved by lensectomy in 5 eyes and lensectomy with intraocular lens implantation in 2 eyes. Primary posterior capsulectomy/subtotal vitrectomy was performed during the primary procedure in 5 eyes (71%). Mean follow-up was 3.8 years (range, 0.5-5.4 years).
RESULTS: Myopia correction averaged 17.3 D. A total of 86% (6 eyes) were corrected within +/- 3 D of the goal refraction and the remaining 14% to within +/- 4 D. Uncorrected visual acuity improved postoperatively in all 7 eyes, albeit modestly (average gain 0.14 Snellen fraction; gain from a mean 20/2550 to a mean 20/130). Myopic regression averaged approximately 0.43 D/year. Capsular opacification necessitated YAG-laser membranectomy in the 2 eyes that had preservation of the posterior capsule at the primary procedure. Retinal detachment has not occurred in any of the eyes during the follow-up period.
CONCLUSIONS: Refractive myopic lensectomy reduced high anisometropia and improved functional vision in children who have high myopia beyond the range of excimer laser correction and who will not wear glasses. Further study is indicated to determine the long-term safety of this procedure in similar pediatric populations.

Entities:  

Mesh:

Year:  2006        PMID: 17140827     DOI: 10.1016/j.jaapos.2006.09.004

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  8 in total

1.  Pediatric Refractive Surgery: A 2015 Perspective.

Authors:  Erin Durrie Stahl
Journal:  Mo Med       Date:  2015 May-Jun

2.  Posterior chamber phakic intraocular lens for the correction of high myopic anisometropic amblyopia in adults.

Authors:  Jing Zhang; Jing Zhuang; Ke-Ming Yu
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

3.  Refractive Surgery for Special-Needs Children with High Myopia.

Authors:  Lawrence Tychsen
Journal:  Mo Med       Date:  2022 Jan-Feb

4.  Clinical effect of rigid gas permeable (RGP) contact lens in improving vision and controlling myopia progression of unilateral high myopic children.

Authors:  Zhengxuan Li; Lu Sun; Hongxin Song; Yaqing Guo
Journal:  Int Ophthalmol       Date:  2022-05-25       Impact factor: 2.029

5.  New advances in amblyopia therapy II: refractive therapies.

Authors:  Courtney L Kraus; Susan M Culican
Journal:  Br J Ophthalmol       Date:  2018-06-05       Impact factor: 4.638

6.  Clear lens extraction for patients who are unfit for laser-assisted in situ keratomileusis and implantable contact lenses in central Indian population.

Authors:  Rajesh Subhash Joshi
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

Review 7.  Refractive lens exchange in modern practice: when and when not to do it?

Authors:  Jorge L Alió; Andrzej Grzybowski; Dorota Romaniuk
Journal:  Eye Vis (Lond)       Date:  2014-12-10

8.  Visual quality observation of clear lens extraction by ultrasonic phacoemulsification and intraocular lens implantation in a child with microspherophakia: A case report.

Authors:  Qian Liu; Xiaogang Wang; Suhua Zhang
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.